Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR: 177-Lutetium-PSMA Neoadjuvant to SBRT for Oligorecurrent Prostate Cancer
NCT05496959Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Sep 2022
- Primary completion
- Sep 2032
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Lu-PNT2002 in prostate cancer (PCa), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Sep 2022; status: active, not recruiting.
02
Drugs
Lu-PNT2002
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05496959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496959.